• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Innate Pharma S.A. ADR (NQ: IPHA )

    1.830 -0.050 (-2.66%)
    Streaming Delayed Price Updated: 3:57 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Innate Pharma S.A. ADR

    < Previous 1 2 3 4 Next >
    Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Earnings Scheduled For March 21, 2024
    Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Regulatory Hurdle For Innate Pharma's Blood Cancer Studies
    The FDA has placed a clinical hold on Innate Pharma SA's (NASDAQ: IPHA) lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201... 
    Via Benzinga
    Exposures Product Safety
    Why Shares of Innate Pharma Jumped Thursday
    The company's collaboration agreement with Sanofi could soon pay off. 
    Via The Motley Fool
    Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
    Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Earnings Scheduled For March 23, 2023
    Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. 
    Via Benzinga
    US Stocks Open Lower; Nasdaq Slides Over 100 Points
    U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday. 
    Via Benzinga
    Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
    Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares jumped 147% to $0.4312. Elys Game Technology and Cloakbook DC have been granted license to open sportsbook in Washington, D.C. 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
    Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
    Via Benzinga
    After Five Years Of Collaboration, Sanofi & Innate Pharma Expand Oncology Pact With Additional Programs
    Via Benzinga
    Why Innate Pharma Shares Are Trading Higher By 24%; Here Are 34 Stocks Moving Premarket
    Gainers AIM ImmunoTech Inc. (NYSE: AIM) shares rose 82.4% to $0.62 in pre-market trading. AIM ImmunoTech recently reported safety, tolerability and biological activity data for intranasal ampligen in... 
    Via Benzinga
    Innate Pharma Highlights Early Lacutamab Data In Aggressive Form Of Blood Cancer
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
      
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning and the news behind them! 
    Via InvestorPlace
    Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday
    Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. 
    Via Benzinga
    Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket
    Gainers FOXO Technologies Inc. (NYSE: FOXO) rose 161% to $10.50 in pre-market trading after dipping 52% on Friday. 
    Via Benzinga
    Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session
    Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74. 
    Via Benzinga
    Earnings Scheduled For September 15, 2022
    Companies Reporting Before The Bell • Boqii Holding (NYSE:BQ) is estimated to report earnings for its first quarter. 
    Via Benzinga
    Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
    Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday. 
    Via Benzinga
    This Biotechnology Stock Is Trading Lower By 77%, Here Are 62 Stocks Moving In Monday's Mid-Day Session
    Gainers Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022. 
    Via Benzinga
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.